Wells Fargo
CALT

Wells Fargo’s Calliditas Therapeutics AB American Depositary Shares CALT Stock Holding History

Wells Fargo’s Portfolio CALT Stock Details CALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-1,500
Closed -$58.5K – 7126
2024
Q2 		$58.5K Sell
1,500
-2,260
-60% -$62.1K ﹤0.01% 5235
2024
Q1 		$79K Buy
3,760
+2,260
+151% +$50.3K ﹤0.01% 5031
2023
Q4 		$38.6K Buy
+1,500
New +$28.1K ﹤0.01% 5371
2022
Q2 		– Sell
-629
Closed -$12K – 7698
2022
Q1 		$12K Buy
629
+345
+121% +$6.92K ﹤0.01% 6219
2021
Q4 		$7K Hold
284
– – ﹤0.01% 6650
2021
Q3 		$6K Hold
284
– – ﹤0.01% 6345
2021
Q2 		$8K Buy
+284
New +$8.13K ﹤0.01% 6213

Other funds holding CALT

CGH
Crossmark Global Holdings Houston, Texas $7.71B AUM 37.66% 1-Year Est. Return
AP
Advisors Preferred Rockville, Maryland $679M AUM 22.19% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
MTIC
Missouri Trust & Investment Company Springfield, Missouri $341M AUM 17.31% 1-Year Est. Return

Wells Fargo's CALT Position: Q3 2024 in Review

Wells Fargo sold out of Calliditas Therapeutics AB American Depositary Shares (CALT) in Q3 2024, closing a stake of 1,500 shares — an estimated $58.5K sold.

Wells Fargo first reported a position in CALT in Q2 2021 and held it in 7 quarters. The position peaked at $79K in Q1 2024. 5 funds tracked by Wall St. Rank hold CALT as of Q3 2024.

  • Wells Fargo reported no remaining Calliditas Therapeutics AB American Depositary Shares position as of Q3 2024 after selling out during the quarter.
  • Wells Fargo sold 1,500 Calliditas Therapeutics AB American Depositary Shares shares in Q3 2024, an estimated $58.5K.
  • Wells Fargo first reported a position in Calliditas Therapeutics AB American Depositary Shares in Q2 2021 and held it in 7 quarters.
  • Wells Fargo's Calliditas Therapeutics AB American Depositary Shares position peaked at $79K in Q1 2024.
  • 5 funds tracked by Wall St. Rank held Calliditas Therapeutics AB American Depositary Shares as of Q3 2024.

Based on Wells Fargo's 13F filing for Q3 2024, filed 13 Nov 2024.